Tin tức & Cập nhật

5-MTHF improves portal pressure reduction with propranolol in cirrhosis patients

04 Oct 2023

Treatment with 5-methyltetrahydrofolate (5-MTHF) significantly enhances the effect of propranolol in reducing hepatic venous pressure gradient (HVPG) in patients with cirrhosis and portal hypertension, a recent study has shown.

5-MTHF improves portal pressure reduction with propranolol in cirrhosis patients

04 Oct 2023

Combination therapy with olmesartan safe, effective in advanced hypertension

04 Oct 2023 bởi

Use of olmesartan in a combination therapy for advanced hypertension results in similar cardiovascular outcomes, including myocardial infarction (MI), relative to active comparators, according to a study. Additionally, there is no convincing evidence that olmesartan is harmful to patients with hypertension.

Combination therapy with olmesartan safe, effective in advanced hypertension

04 Oct 2023

Hepatocyte-derived biomarkers predict liver-related events in alcohol-related cirrhosis

04 Oct 2023

The combination of hepatocyte-derived biomarkers and FibroTest or model for end-stage liver disease (MELD) scores can help identify patients with Child-Pugh class A alcohol-related cirrhosis who are prone to liver-related events at 2 years, reports a study.

Hepatocyte-derived biomarkers predict liver-related events in alcohol-related cirrhosis

04 Oct 2023

COVID vs non-COVID ARDS: Are both mentally distressing for patients’ kin?

04 Oct 2023 bởi

Mental health symptoms of family members of patients hospitalized for acute respiratory distress syndrome (ARDS) were similar at 12 months regardless of whether it was caused by COVID-19 or not, a prospective cohort study suggests.

COVID vs non-COVID ARDS: Are both mentally distressing for patients’ kin?

04 Oct 2023

Long-term prophylaxis reduces attacks, improves QoL in Chinese patients with hereditary angioedema

04 Oct 2023 bởi

In a prospective study by the University of Hong Kong, long-term prophylaxis (LTP) with garadacimab or lanadelumab reduces attacks and improves quality of life (QoL) in Chinese patients with hereditary angioedema (HAE) who experienced frequent attacks. No adverse events (AEs) were reported.

Long-term prophylaxis reduces attacks, improves QoL in Chinese patients with hereditary angioedema

04 Oct 2023

Sử dụng PPI có thể khiến trẻ dễ bị nhiễm trùng nghiêm trọng

04 Oct 2023 bởi

Theo một nghiên cứu, việc sử dụng thuốc ức chế bơm proton (PPI) có thể làm tăng nguy cơ nhiễm trùng nghiêm trọng ở trẻ nhỏ.

Sử dụng PPI có thể khiến trẻ dễ bị nhiễm trùng nghiêm trọng

04 Oct 2023

Ranitidine use not linked to increased cancer incidence

04 Oct 2023

Individuals with ranitidine exposure do not appear to be at increased risk of cancer compared with those who have exposure to other histamine-2 receptor antagonists (H2RAs), according to a study.

Ranitidine use not linked to increased cancer incidence

04 Oct 2023

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

04 Oct 2023 bởi

First-line treatment with dabrafenib plus trametinib significantly increased overall response rate (ORR) in paediatric patients with low-grade glioma harbouring BRAF V600 mutations compared with standard chemotherapy, according to a recent study.

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

04 Oct 2023

Semaglutide phối hợp insulin degludec duy trì kiểm soát đường huyết ở bệnh nhân đái tháo đường type 2

04 Oct 2023 bởi

Theo nghiên cứu TRANSITION-T2D được trình bày tại ADA 2023, điều trị với semaglutide tiêm dưới da 1 lần/tuần và insulin degludec 1 lần/ngày giúp duy trì mức HbA1c ≤7.5% ở những bệnh nhân kiểm soát tốt đái tháo đường (ĐTĐ) type 2 đang sử dụng phác đồ tiêm insulin nhiều lần trong ngày (MDI).

Semaglutide phối hợp insulin degludec duy trì kiểm soát đường huyết ở bệnh nhân đái tháo đường type 2

04 Oct 2023

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs

03 Oct 2023 bởi

Among patients with hepatitis C virus (HCV) infection, the likelihood of achieving sustained virologic response (SVR) with direct-acting antivirals (DAAs) does not appear to be reduced among those who use alcohol or have alcohol use disorder (AUD), according to a study.

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs

03 Oct 2023

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

5-MTHF improves portal pressure reduction with propranolol in cirrhosis patients

5-MTHF improves portal pressure reduction with propranolol in cirrhosis patients

Combination therapy with olmesartan safe, effective in advanced hypertension

Combination therapy with olmesartan safe, effective in advanced hypertension

Hepatocyte-derived biomarkers predict liver-related events in alcohol-related cirrhosis

Hepatocyte-derived biomarkers predict liver-related events in alcohol-related cirrhosis

COVID vs non-COVID ARDS: Are both mentally distressing for patients’ kin?

COVID vs non-COVID ARDS: Are both mentally distressing for patients’ kin?

Long-term prophylaxis reduces attacks, improves QoL in Chinese patients with hereditary angioedema

Long-term prophylaxis reduces attacks, improves QoL in Chinese patients with hereditary angioedema

Sử dụng PPI có thể khiến trẻ dễ bị nhiễm trùng nghiêm trọng

Sử dụng PPI có thể khiến trẻ dễ bị nhiễm trùng nghiêm trọng

Ranitidine use not linked to increased cancer incidence

Ranitidine use not linked to increased cancer incidence

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

Dabrafenib-trametinib combo improves response in BRAF V600-mutant paediatric glioma

Semaglutide phối hợp insulin degludec duy trì kiểm soát đường huyết ở bệnh nhân đái tháo đường type 2

Semaglutide phối hợp insulin degludec duy trì kiểm soát đường huyết ở bệnh nhân đái tháo đường type 2

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs

Heavy alcohol use among hepatitis C patients does not weaken response to DAAs